Original contributionExpression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/Cyclin D1 gene☆,☆☆
References (37)
- et al.
- et al.
Genotypic characterization of centrocytic lymphoma: Frequent rearrangement of the chromosome 11 bcl-1 locus
Blood
(1990) - et al.
Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: Analysis with multiple breakpoint probes
Blood
(1991) - et al.
Cyclin Dl overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement
Ann Oncol
(1994) - et al.
Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation
Blood
(1990) - et al.
Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas
Blood
(1994) - et al.
Antigen expression and polymerase chain reaction amplification of mantle cell lymphomas
Blood
(1994) - et al.
Growth fraction in centrocytic and follicular center cell lymphomas: Assessment in paraffin sections with a proliferating cell nuclear antigen antibody and morphometric correlates
Hum Pathol
(1993) - et al.
Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias
Blood
(1993) - et al.
PRAD-1/Cyclin Dl gene overexpression in chronic lymphoproliferative disorders: A highly specific marker of mantle cell lymphoma
Blood
(1994)
Splenic lymphoma with villous lymphocytes: Analysis of bcl-1 rearrangements and expression of the cyclin Dl gene
Blood
Cytological and functional criteria for the classification of malignant lymphomata
Br J Cancer
Classification of non-Hodgkin's lymphomas
Lancet
Morphological and immunological definition of a malignant lymphoma derived from germinal-centre cells with cleaved nuclei (centrocytes)
Br J Cancer
Centrocytic lymphoma: A distinct clinicopathologic and immunologic entity
Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies: Follicular and diffuse lymphomas of small-cleaved-cell type are related but distinct entities
Am J Pathol
Mantle cell lymphoma: A proposal for unification of morphologic, immunologic, and molecular data
Am J Surg Pathol
Centrocytic lymphoma: A distinct clinicopathologic, immunophenotypic, and genotypic entity
Pathol Annu
Cited by (101)
Treatment of mantle cell lymphoma in older adults
2018, Journal of Geriatric OncologyCitation Excerpt :On pathologic evaluation morphology varies from small to large atypical lymphocytes. Diagnosis requires a combination of flow cytometry (CD20 +, CD5 +, CD10 −, CD23 −), fluorescence in-situ hybridization for t(11;14), and immunohistochemical staining for cyclin D1 overexpression [6,7]. The clinical behavior of MCL is typically that of an aggressive lymphoma similar to the more common diffuse large B cell lymphoma (DLBCL), with development of symptoms over weeks to several months and a rapid response after initiation of treatment.
Candidate genes contributing to the aggressive phenotype of mantle cell lymphoma
2011, Acta HistochemicaCitation Excerpt :Pre-GC SLL lacks the genetic refinements observed in generating high-affinity antibodies during the GC reaction and can have a more aggressive clinical course than does post-GC SLL, which shows no genetic evidence of antibody gene alterations from passing through the GC (Klein and Dalla-Favera, 2008; Perez-Galan et al., 2010). Unlike MCL and many other classes of lymphoma, pre- or post-GC CLL and SLL are not characterized by a common oncogenic translocation (Guipaud et al., 2003; Swerdlow et al., 1995). Despite a poor response to conventional therapies, post-GC CLL/SLL is most often characterized by a prolonged indolent period with a median survival time between seven and ten years (Binet et al., 1981; Dighiero et al., 1981).
Immunohistology of Non-Hodgkin Lymphoma
2011, Diagnostic ImmunohistochemistryImmunohistology of Non-Hodgkin Lymphoma: Follicular Lymphoma versus Reactive Hyperplasia.
2010, Diagnostic Immunohistochemistry: Theranostic and Genomic Applications, Expert Consult
- ☆
Supported in part by American Cancer Society Research Grant CB69529 and NCI Cancer Center Support Grant P30-44579 (MEW).
- ☆☆
This work was also supported in part by the Pathology Education and Research Foundation, Pittsburgh, PA.